Biogen (BIIB) vs Halozyme Therapeutics (HALO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Halozyme Therapeutics (HALO) has outperformed Biogen (BIIB) over the past year, gaining 69.6% versus a gain of 50.9%. Over five years, HALO leads with a +192.4% price change compared with -22.3% for BIIB. Biogen is the larger company by market cap ($33.35 billion vs $12.53 billion), about 2.7 times the size, while Halozyme Therapeutics is growing revenue faster (+37.6% vs +2.2%).
On valuation, Halozyme Therapeutics trades at a lower forward P/E (10.4x vs 13.6x for Biogen). Halozyme Therapeutics converts more of its revenue into profit, with a net margin of 22.7% versus 13.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | HALO |
|---|---|---|
| Share price | $225.71 | $110.42 |
| Market cap | $33.35B | $12.53B |
| 1-day change | +3.33% | +0.53% |
| YTD return | +28.25% | +64.07% |
| 1-year return | +50.87% | +69.59% |
| 5-year return | -22.32% | +192.43% |
| P/E ratio (TTM) | 38.78 | 32.29 |
| Forward P/E | 13.65 | 10.39 |
| EPS (TTM) | $5.82 | $3.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $1.40B |
| Revenue growth (YoY) | +2.22% | +37.55% |
| Net income (latest FY) | $1.29B | $316.89M |
| Gross margin | 75.69% | 83.62% |
| Operating margin | — | 33.58% |
| Net margin | 13.07% | 22.69% |
| 52-week high | $230.49 | $116.85 |
| 52-week low | $138.00 | $61.23 |
| Distance from 52-week high | -2.07% | -5.50% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +5.52% | -9.84% |
| Average volume | 1.06M | 2.19M |
| Shares outstanding | 147.75M | 113.50M |
| Employees | 7,500 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biogen is about 2.7 times larger than Halozyme Therapeutics by market value ($33.35B vs $12.53B).
- HALO has outperformed BIIB by 18.7 percentage points over the past year.
- Halozyme Therapeutics is more profitable, keeping 22.7 cents of every revenue dollar as net income versus 13.1 cents for Biogen.
- Halozyme Therapeutics grew revenue faster in its latest fiscal year (+37.55% vs +2.22%).
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About Halozyme Therapeutics
HALO stock →Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 423 employees
BIIB vs HALO FAQ
Which is bigger, Biogen or Halozyme Therapeutics?
Biogen (BIIB) is larger, with a market capitalization of $33.35B compared with $12.53B for Halozyme Therapeutics (HALO).
Which stock has performed better over the past year, BIIB or HALO?
HALO returned +69.59% over the past 12 months, compared with +50.87% for BIIB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIIB or HALO?
HALO has the lower trailing P/E at 32.3, versus 38.8 for BIIB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biogen and Halozyme Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.